TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB92584

Peptide_Name

IDP-LS13

Activity

Anticancer

Activity_category_statistics

Cancer-related peptides

Database_Source

CancerPPD 2.0

Sequence_Type

standard

Has_Modification No

Description A 17-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.

Modification

Chemical: -(CH2)6-CH=CH-(CH2)3 Chemical: a biradical linker links R(8) and R(15)

Sequence

RKRRNDLRSRFLALRDQ

FASTA

>TPDB92584|Anticancer|length=17
RKRRNDLRSRFLALRDQ

Formula C92H162N38O25

Absent Amino Acids CEGHIMPTWYV

Common Amino Acids R

Mass 2200.54

PI 12.40

Basic Residues 7

Acidic Residues 2

Hydrophobic Residues 5

Net Charge +5

Boman Index 6.46

Hydrophobicity -1.747

Aliphatic Index 74.71

Half Life

Mammalian: 1 hour Yeast: 2 min E.coli: 2 min

Extinction Coefficient Cystines 0

Absorbance 280nm 0.00

Polar Residues 3

number

1

A

6

R

1

N

2

D

0

C

0

E

1

Q

0

G

0

H

0

I

3

L

1

K

0

M

1

F

0

P

1

S

0

T

0

W

0

Y

0

V

Amino Acid Distribution

A: 1 R: 6 N: 1 D: 2 C: 0 E: 0 Q: 1 G: 0 H: 0 I: 0 L: 3 K: 1 M: 0 F: 1 P: 0 S: 1 T: 0 W: 0 Y: 0 V: 0

Length

17

Formula

C92H162N38O25

Mass

2200.54

PI

12.40

Net Charge

+5

Boman Index

6.46

Hydrophobicity

-1.747

C_terminal_Modification

Free

Chemical_Modification

-(CH2)6-CH=CH-(CH2)3 a biradical linker links R(8) and R(15)

Chirality

L

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Anticancer

Origin

Synthetic

Evidence 1 Activity

Activity

Activity Endpoint EC50

Activity Raw

EC50 ~ 10 µM

Detail Source Activity Anticancer

Activity Measurement 10 µM

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay MTT/Alamamar-Blue/Hexosaminidase activity test

Testing Time 48-72 h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2020

Patents US20200239547A1

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint EC50

Activity Raw

EC50 ~ 7 µM

Detail Source Activity Anticancer

Activity Measurement 7 µM

Target

Cancer Type Leukemia Cancer

Cell Line HL-60

Tissue Affected Blood

Assay & Model

Assay MTT/Alamamar-Blue/Hexosaminidase activity test

Testing Time 48-72 h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2020

Patents US20200239547A1

Evidence 3 Activity

Activity

Activity Endpoint EC50

Activity Raw

EC50 ~ 9 µM

Detail Source Activity Anticancer

Activity Measurement 9 µM

Target

Cancer Type Leukemia Cancer

Cell Line RPMI

Tissue Affected Blood

Assay & Model

Assay MTT/Alamamar-Blue/Hexosaminidase activity test

Testing Time 48-72 h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2020

Patents US20200239547A1

Evidence 4 Activity

Activity

Activity Endpoint EC50

Activity Raw

EC50 ~ 10 µM

Detail Source Activity Anticancer

Activity Measurement 10 µM

Target

Cancer Type Lymphoma Cancer

Cell Line U266

Tissue Affected Blood

Assay & Model

Assay MTT/Alamamar-Blue/Hexosaminidase activity test

Testing Time 48-72 h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2020

Patents US20200239547A1